Tekmira Conference Call and Webcast Advisory Corporate

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Tekmira Conference Call and Webcast Advisory Corporate Update and First Quarter Financial Results

VANCOUVER, British Columbia, April 22, 2015 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (Nasdaq: TKMR ), a biopharmaceutical company dedicated to discovering, developing and commercializing a cure for patients suffering from chronic hepatitis B infection (HBV), announced that it will hold a conference call and webcast on Wednesday, May 6, 2015 at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time) to provide a corporate update and first quarter financial results.

Conference Call and Webcast Information

A live webcast of the call can be accessed through the Investor section of Tekmira's website at www.tekmira.com . Alternatively, to access the conference call, please dial 914-495-8556 or 1-866-393-1607.

An archived webcast will be available on the Tekmira website approximately two hours after the event. A replay of the conference call can be accessed by calling 404-537-3406 or 1-855-859-2056 and referencing conference ID 20892540.

About Tekmira

Tekmira Pharmaceuticals Corporation is a biopharmaceutical company dedicated to discovering, developing and commercializing a cure for patients suffering from chronic hepatitis B infection (HBV). Our strategy is to target the three pillars necessary to develop a curative regimen for HBV, including suppressing HBV replication within liver cells, stimulating and reactivating the body's immune system so that it can mount an effective defense against the virus and, most importantly, eliminating the reservoir of viral genomic material known as covalently closed circular DNA, or cccDNA, that is the source of HBV persistence. Our portfolio of assets includes eight drug candidates for use in combination to develop a cure for HBV, and includes our product TKM-HBV currently in Phase 1 clinical studies.

We also have a pipeline of non-HBV assets in oncology, anti-viral and metabolic therapeutics that leverage our expertise in RNA interference (RNAi) therapeutics and leading Lipid Nanoparticle (LNP) technology. RNAi and LNP technology have the potential to generate new therapeutics that take advantage of the body's own natural processes to silence disease causing genes, or more specifically, to eliminate specific gene-products, from the cell. We intend to maximize the value of our non-HBV assets in the clinic, namely: TKM-PLK1 for advanced gastrointestinal neuroendocrine tumors, adrenocortical carcinoma and hepatocellular carcinoma; and TKM-Ebola, and TKM-Ebola-Guinea for ebola virus disease; as well as our preclinical programs in metabolic disorders and filoviruses.

Tekmira is headquartered in Vancouver, BC, Canada with offices in Doylestown, PA, USA. For more information, visit www.tekmira.com .

Investors Adam Cutler Senior Vice President, Corporate Affairs Phone: 604.419.3200 Email: Julie P. Rezler Director, Investor Relations & Corporate Communications Phone: 604-419-3200 Email: Media Please direct all media inquiries to:

Scroll down for more posts ▼

Top 10 Most Recent News Articles

AI Use Hits 93% in Health Systems' Digital Shift

Updated Category News Views 33

Healthcare's AI Surge: Jumping the Adoption Hurdle The digital health landscape isn't just humming along—it's hitting high gear. AI, once the shiny toy in innovation's toolkit, is now a fixture in 93.2% of healthcare systems according to CHIME's latest findings. For anyone keeping score, that's a hefty leap and paints a picture where AI isn't just in the game, it's...

Continue Reading
Dana Concludes Tender Offers for Senior Notes

Updated Category News Views 72

An Investor's Glance at Dana's Strategic Moves Dana Incorporated (NYSE: DAN) just pulled a bold move with their tender offers, snapping up a hefty $357,873,000 in outstanding principal on their senior notes. This isn’t just pocket change; folks holding out for securities can feel the tension of watching big numbers get shuffled around. You gotta wonder, what's the play...

Continue Reading
Later's NYC Summit Reinvents Social Commerce Game Plan

Updated Category News Views 120

Creators and Corporates Collide Imagine this: an NYC stage not adorned with Broadway's finest, but with digital maestros steering a new age in social commerce. That's what Later is betting on with their Creator Live summit, debuting in the bustling heart of New York City. We're talking about influencers not just as Instagram stars, but as key players in a $480 billion...

Continue Reading
Koppers Faces SEC Scrutiny After Earnings Miss

Updated Category News Views 124

Koppers' Third-Quarter Blues: Missing the Mark Koppers Holdings Inc. (NYSE: KOP) took a hard hit this quarter, missing Wall Street's earnings expectations by a mile. The adjusted earnings per share came in at just $0.77, while the suits down on Wall Street were expecting something closer to $1.34 to $1.37. Now, if you’re holding KOP in your portfolio, you're probably...

Continue Reading
National Police Assoc. Urges House to Pass PTSD Act

Updated Category News Views 101

An Urgent Call for Action on PTSD Support Alright folks, this ain't your typical investment rundown, but it's got stakes just the same. The National Police Association is sounding the horn for the House to pass the Fighting Post-Traumatic Stress Disorder Act of 2025 (S. 825). Now, if you've been around the block, you know legislation can play out like a market...

Continue Reading
CR&R Workers Join Teamsters, Fight for Fair Conditions

Updated Category News Views 74

Waste Workers Push Back Against Corporate Pressure The Southern California sun isn't the only thing heating up these days; the waste workers at CR&R Environmental Services have cranked up the heat by voting to join Teamsters Local 396. It's like Groundhog Day in the world of labor rights—same story, different locale, workers banding together for a fair shot. A Stand...

Continue Reading
SOCSA: The Future of Safety in Confined Spaces?

Updated Category News Views 68

Autonomous Tech Meets Safety Regulations Some days innovation hits like a ton of bricks, and here we go again—this time with a gizmo aiming to shake up the safety game in confined spaces. Enter the SOCSA, the Self Operating Confined Space Attendant, designed by a seasoned agriculture worker who's had a ringside seat to enough OSHA rule breaches to fill a book. But ain't...

Continue Reading
Accuray Finishes Key Deal, Resetting Financial Trajectory

Updated Category News Views 112

Accuray Secures the Deal, But Is the Future Bright? Every now and then in the investing world, a company pulls off a maneuver that you wish you’d thought of first. Today, folks, it's Accuray's turn. They've just wrapped up a monstrous transaction with TCW – their primary lender and shareholder – that has them feeling optimistic about the road ahead. Bold Moves to...

Continue Reading
Citigroup, Scotia Aid TSTT in $500M Note Offering

Updated Category News Views 49

Kicking off with a banger that’s got financial water coolers buzzing, Greenberg Traurig just pulled a rabbit out of the hat helping Citigroup and Scotia Capital orchestrate a chunky near $500 million dual-currency notes deal for Telecommunications Services of Trinidad and Tobago Limited (TSTT). Now, this isn’t your run-of-the-mill market maneuver. We're seeing a...

Continue Reading
Agiloft Navigates New Growth Phase with Key Leadership

Updated Category News Views 142

Leadership Shifts Steer Agiloft's EMEA Journey Agiloft's latest shake-ups in leadership signal a determined charge through EMEA's bustling markets. Nick Bowles, a seasoned veteran in enterprise software, steps into the limelight as Senior Vice President, while Jim Leason shifts gears into a customer-focused advisory role. These aren’t just routine hiring...

Continue Reading

Top 5 Most Recently Viewed Articles

Exploring Innovative Glaucoma Research with 2025 Grants Announcement

Updated Category News Views 283

2025 Shaffer Grants Foster Groundbreaking Glaucoma Research In an exciting development in the field of ophthalmology, the Glaucoma Research Foundation (GRF) has revealed its nine recipients of the prestigious 2025 Shaffer Research Grants, totaling $55,000. These grants are designed to support innovative research aimed at understanding and potentially transforming...

Continue Reading
Beyond Air's Participation in Upcoming Investment Conference

Updated Category News Views 141

Beyond Air to Engage at H.C. Wainwright Conference Beyond Air, Inc. (NASDAQ: XAIR), a pioneering biopharmaceutical company known for its innovative approach to medical devices, recently declared its commitment to participate in the H.C. Wainwright 27th Annual Global Investment Conference. Steve Lisi, the Chairman and Chief Executive Officer, will represent the company at...

Continue Reading
Investors Urged to Act on Sable Offshore Corp. Securities Case

Updated Category News Views 150

Investors Now Have an Important Opportunity with Sable Offshore Corp. In light of recent developments, investor awareness regarding Sable Offshore Corp. (NYSE: SOC) has become crucial. Allegations of securities fraud have emerged, prompting a thorough investigation led by the DJS Law Group. This investigation centers around potential violations of securities laws, raising...

Continue Reading
Coeur Mining Prepares for Q4 and Full-Year 2024 Earnings Results

Updated Category News Views 131

Coeur Mining Earnings Report Announcement Coeur Mining, Inc. (NYSE: CDE) is gearing up to release its operational and financial outcomes for the fourth quarter and the full year of 2024. This report is poised to be made public following the close of the New York Stock Exchange on a specified date. Following the announcement, Coeur will host a conference call to discuss...

Continue Reading
Exploring Option Care Health's Robust Financial Victory for 2024

Updated Category News Views 85

Financial Overview of Option Care Health Option Care Health, Inc. (NASDAQ: OPCH), recognized as the largest independent provider of home and alternate site infusion services, recently shared its financial results for the fourth quarter and the entirety of 2024. Their performance reflects strategic execution and strong market demand despite a challenging environment....

Continue Reading